I think you forget Shaw also put about 300k of his own money into TAUG at higher prices.
As far as 25 percent return, these are all high risk very high return investments.
The biotech that you like to slam could easily return TAUG in excess of 5 to 10 million dollars within a year.
That is conservative (on depression alone)based on other moves in the space like the Naurex drug sale ( 2 billion) sale, alchemy moves, and Sage market cap moving up 2 billion dollars in one day on a phase 2 depression trial in December. Johnson and Johnson should be close to submitting NDA on ketamine spray early 2019. All of these drugs have either side effects or need to be administered by a doctor.
Speaking of Naurex, they recently spun off its pain drug at 600 million and is now a billion dollar market cap.
Taug holds a huge position in a company that not only is on the forefront of depression, but has indications for pain, Parkinson’s and Hodgkinsons, not to mention stem cell. And it is oral.
Oppenheimer and other firms state it is worth nearly 5 times what it is trading at. Chardon puts it at 22 after phase 2.
Let’s see what happens at the end of Q1, that would give Taug about 1 year to see how the strategy they are using works.
